Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, filed on Tuesday with the SEC to raise up to $14 million in an initial public offering.
Telomir Pharmaceuticals is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapy for human stem cells. Based on its preclinical studies, the company believes that TELOMIR-1 may potentially serve as a metal enzyme inhibitor of essential metals such as zinc and copper. Telomir's initial focus will be on treatments to inhibit the production of pro-inflammatory cytokines, with a goal of advancing TELOMIR-1 in the US for the treatment of age-related inflammatory conditions such as hemochromatosis and osteoarthritis, as well as in post-chemotherapy recovery.
The Baltimore, MD-based company was founded in 2021 and plans to list on the Nasdaq under the symbol TELO. Kingswood Capital Markets is the sole bookrunner on the deal. No pricing terms were disclosed.
